Medical Advocates
Atazanavir (Reyataz)

Conference Citations

15th CROI
4th IAS Conference
14th CROI
Conference Archives

Atazanavir Main Page

Main New/Newsworthy

Home Page

Last updated: June 02, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

15th CROI

NEWS RELEASE
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ®
(atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks
in Previously Untreated HIV-Infected Adult Patients
BMS February 06, 2008

Efficacy and Safety of Once-daily Atazanavir/Ritonavir Compared to Twice-daily Lopinavir/Ritonavir,
Each in Combination with Tenofovir and Emtricitabine in ARV-naive HIV-1-infected Subjects:
The CASTLE Study, 48-week Results
J-M Molina, J A Villanueva, J Echevarria, et al

POSTER
Switch from Ritonavir-boosted to Unboosted Atazanavir Guided by Monitoring Atazanavir
Concentrations in a Clinical Setting
SRodriguez-Novoa, J Morello
PDF Poster Abstract

POSTER
Treatment Responses to Atazanavir-containing HAART in a Drug-naïve Pediatric Population
in South Africa
T Meyers R Rutstein, P Samson,
PDF Poster Abstract

POSTER
Absence of Protease Resistance with Virologic Rebound by Single Genome Sequencing on
Atazanavir/Ritonavir as Simplified Maintenance Therapy: ACTG 5201
J McKinnon, T Wilkin, S Swindells, et al
PDF Poster Abstract

POSTER
Hepatic Transaminase Elevations and Gastrointestinal Intolerance when HIV-negative Healthy
Volunteers on Rifampin add Twice-daily Atazanavir ( 300 mg)/Ritonavir ( 100 mg): ACTG Protocol
A5213
D Haas, S Koletar, L Laughlin, et al
PDF Poster Abstract

POSTER
Rates of Ritonavir Non-adherence and Dose Staggering in HIV⁺ Patients Receiving RTV-boosted
Atazanavir or Fosamprenavir
J Shuter, R Rode, J Sarlo, B Zingman
PDF Poster Abstract

POSTER
Atazanavir in Pregnancy: Influence on Neonatal Hyperbilirubinemia
C Ferreira, C Floch-Tudal, F Meier, et al
PDF Poster Abstract

Steady State Pharmacokinetics and Safety of Atazanavir after Treatment with ATV 300 mg
Once Daily/Ritonavir 100 mg Once Daily + ZDV/3TC during the Third Trimester in HIV⁺ Women
T Eley, E Vandeloise, M Child

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Efficacity, safety, and plasma concentration of a double boosted PI combination atazanavir
(ATV/fosamprenavir(FPV)/ritonavir(RTV) a once daily regimen in HIV-1 infected patients: the
TELAZ study
Kirstetter M, Peytavin G, Delaugerre C, et al
Abstract

Hepatic effects of atazanavir plus ritonavir (ATV/r)-based combinations in patients with
hepatitis virus coinfection: relationship with pre-existing liver damage
Abdel-Kader L, Santos J, Rivero A, et al
Abstract

Exploring the impact of therapeutic drug monitoring (TDM) in patients receiving atazanavir–
ritonavir (ATV/r) boosted regimens
Guillemi S, Harrigan R, Yip B, et al
Abstract

Efficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients
with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study
Mallolas J, Podzamczer D, Domingo P, et al
Abstract

Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects,
both with and without ritonavir: 96-week results from AI424089
Malan N, Krantz E, David N, et al
Abstract

Once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir:
60-week efficacy and metabolic effects
Manosuthi W, Chaovavanich A, Prasithsirikul W, et al
Abstract

Treatment simplification to an atazanavir-containing regimen: impact on patient´s perception of
adverse events severity
Gatell JM, L'Italien G, Wirtz V, et al
Abstract

Metabolic results in the Simplification Lopinavir to Atazanavir Trial (SLOAT)
Ramírez-Olivencia G, Ruiz-Sancho A, Martín-Carbonero L, et al
Abstract

Pharmacokinetics of atazanavir in HIV-1-HCV co-infected patients
Gatti F, Nasta P, Matti A, et al
Abstract

HIV-1 protease mutation L76V enhances susceptibility to atazanavir and saquinavir in multidrug-
resistant HIV-1 infected patients
Braun P, Wiesmann F, Walter H, et al
Abstract

Efficacy and safety of atazanavir in HIV-infected patients with liver cirrhosis
Hermida Donate JM, Quereda C, Moreno A, et al
Abstract

Efficacy and safety of non-boosted to ritonavir-boosted atazanavir among antiretroviral naïve
patients
Horberg M, Klein D, Hurley L, et al
Abstract

14th CROI

Assessment of Pharmacokinetic/Pharmacodynamic Relationships through 48 Weeks from a Study
in HIV⁺, ART-naive Subjects Receiving Antiretroviral Regimens Containing Atazanavir 400 mg or
Atazanavir/Ritonavir 300/100 mg Once Daily
R Bertz, Y Wang, L Mahnke, et al
Abstract
The PACTG 1020A Protocol: Atazanavir with or without Ritonavir in HIV-infected Infants, Children,
and Adolescents
R Rutstein, P Samson, J Kiser, et al
Abstract
Effect of Rifampin on Pharmacokinetics and Safety of Twice-daily Atazanavir: ACTG Protocol A5213
E Acosta, M Kendall, J Gerber, et al
Abstract
Effect of Famotidine 20- and 40-mg Dosing Regimens on the Bioavailability of Atazanavir with Ritonavir
in Combination with Tenofovir in Healthy Subjects
S Agarwala, A Persson, T Eley, et al
Abstract
Atazanavir Use in Pregnancy: A Report of 33 Cases
M Natha, P Hay, G Taylor, et al
Abstract
Effects of Atazanavir or Saquinavir Once Daily with Ritonavir 100 mg and Tenofovir/Emtricitabine as
Initial Therapy for HIV-1 Infection on Peripheral Glucose Disposal: A Randomized Open-label Study
A Jackson, N Patel, G Lo, et al
Abstract

POSTER
Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir of
HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort
D Desbois, G Peytavin, S Matheron, et al
PDF Poster     Abstract

POSTER
Atazanavir-based HAART in Pregnancy
D Ripamonti, D Cattaneo, M Airoldi, et al
PDF Poster     Abstract
POSTER
Body Composition Changes in ART-naive Subjects Treated with Atazanavir or Atazanavir/Ritonavir-
based Once-daily HAART: 48-Week Computed Tomography and DEXA Data
D McGrath, D Frederick, V Wirtz, et al
PDF Poster     Abstract

POSTER
Gilbert’s Disease and Atazanavir: From Phenotype to UDP-glucuronosyltransferease Haplotype
T Lankisch, G Behrens, U Moebius, et al
PDF Poster    Abstract

Atazanavir Main Page

Main New/Newsworthy

Home Page